Precigen, Inc. (NASDAQ:PGEN – Get Rating) COO Rutul R. Shah bought 9,142 shares of Precigen stock in a transaction on Friday, January 27th. The shares were purchased at an average price of $1.75 per share, for a total transaction of $15,998.50. Following the acquisition, the chief operating officer now directly owns 62,037 shares in the company, valued at approximately $108,564.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Precigen Trading Down 4.9 %
Shares of PGEN opened at $1.56 on Tuesday. The business's fifty day simple moving average is $1.69 and its two-hundred day simple moving average is $1.92. Precigen, Inc. has a 12 month low of $1.12 and a 12 month high of $2.90. The company has a market cap of $324.71 million, a price-to-earnings ratio of 13.00 and a beta of 1.89.
Get Precigen alerts:Precigen (NASDAQ:PGEN – Get Rating) last issued its earnings results on Wednesday, November 9th. The biotechnology company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.10 by ($0.14). Precigen had a net margin of 33.55% and a negative return on equity of 82.23%. The business had revenue of $16.72 million for the quarter, compared to analysts' expectations of $51.72 million. As a group, research analysts forecast that Precigen, Inc. will post -0.41 EPS for the current year.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on the company. StockNews.com assumed coverage on Precigen in a research note on Wednesday, October 12th. They issued a "sell" rating on the stock. Cantor Fitzgerald upped their price target on Precigen from $7.00 to $10.00 and gave the stock an "overweight" rating in a research note on Monday. Finally, JMP Securities upped their price target on Precigen from $13.00 to $14.00 and gave the stock a "market outperform" rating in a research note on Thursday, November 10th.Hedge Funds Weigh In On Precigen
Hedge funds and other institutional investors have recently modified their holdings of the company. Cresset Asset Management LLC bought a new position in shares of Precigen during the 1st quarter valued at $25,000. Sanford Advisory Services LLC bought a new position in shares of Precigen during the 3rd quarter valued at $32,000. The Manufacturers Life Insurance Company bought a new position in shares of Precigen during the 3rd quarter valued at $47,000. Inspire Investing LLC lifted its holdings in shares of Precigen by 57.5% during the 2nd quarter. Inspire Investing LLC now owns 26,170 shares of the biotechnology company's stock valued at $35,000 after buying an additional 9,554 shares during the period. Finally, Barclays PLC lifted its holdings in shares of Precigen by 416.4% during the 3rd quarter. Barclays PLC now owns 26,184 shares of the biotechnology company's stock valued at $55,000 after buying an additional 21,114 shares during the period.
About Precigen
(Get Rating)
Precigen, Inc is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases.
Further Reading
- Get a free copy of the StockNews.com research report on Precigen (PGEN)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.